Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Long-Term Investments (2016 - 2025)

Agios Pharmaceuticals' Long-Term Investments history spans 13 years, with the latest figure at $310.0 million for Q4 2025.

  • For Q4 2025, Long-Term Investments fell 51.43% year-over-year to $310.0 million; the TTM value through Dec 2025 reached $310.0 million, down 51.43%, while the annual FY2025 figure was $310.0 million, 51.43% down from the prior year.
  • Long-Term Investments reached $310.0 million in Q4 2025 per AGIO's latest filing, up from $304.3 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $655.9 million in Q3 2024 to a low of $21.6 million in Q1 2021.
  • Average Long-Term Investments over 5 years is $271.5 million, with a median of $269.1 million recorded in 2021.
  • Peak YoY movement for Long-Term Investments: tumbled 90.62% in 2023, then skyrocketed 2068.58% in 2024.
  • A 5-year view of Long-Term Investments shows it stood at $266.4 million in 2021, then rose by 17.83% to $313.9 million in 2022, then crashed by 90.62% to $29.4 million in 2023, then surged by 2068.58% to $638.3 million in 2024, then plummeted by 51.43% to $310.0 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Long-Term Investments are $310.0 million (Q4 2025), $304.3 million (Q3 2025), and $400.5 million (Q2 2025).